CN101461857A - Medicament for treating severe hepatitis - Google Patents

Medicament for treating severe hepatitis Download PDF

Info

Publication number
CN101461857A
CN101461857A CNA2009101172019A CN200910117201A CN101461857A CN 101461857 A CN101461857 A CN 101461857A CN A2009101172019 A CNA2009101172019 A CN A2009101172019A CN 200910117201 A CN200910117201 A CN 200910117201A CN 101461857 A CN101461857 A CN 101461857A
Authority
CN
China
Prior art keywords
portions
parts
radix
medicine
rhizoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2009101172019A
Other languages
Chinese (zh)
Other versions
CN101461857B (en
Inventor
刘鹏霞
李斌
赵岩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2009101172019A priority Critical patent/CN101461857B/en
Publication of CN101461857A publication Critical patent/CN101461857A/en
Application granted granted Critical
Publication of CN101461857B publication Critical patent/CN101461857B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicine prepared from pure traditional Chinese medicines for treating fatal hepatitis with good treatment effect and small toxic and side effects. The medicine for treating fatal hepatitis comprises the following raw materials by weight portion: 30 to 60 portions of Artemisia capillaries, 10 to 15 portions of Scutellaria baicalensis, 9 to 12 portions of Coptis chinensis, 8 to 12 portions of rhubarb, 10 to 15 portions of cape jasmine, 15 to 20 portions of Asiatic plantain seeds, 15 to 18 portions of Poria coccus, 15 to 20 portions of Atractylis ovata, 15 to 20 portions of Chinese hawkthorn, 25 to 30 portions of Salvia miltiorrhiza, 15 to 20 portions of Astragalus membranaceus, 3 to 5 portions of liquorice, 15 to 30 portions of Cyrtomium fortunei and 20 to 60 portions of oldenlandia diffusa. The traditional Chinese medicine has obvious treatment effect on acute fatal hepatitis and subacute fatal hepatitis with short disease course. The medicine consists of pure traditional Chinese medicines, and has good treatment effect and small toxic and side effects.

Description

The medicine of treatment hepatitis gravis
Technical field the invention belongs to technical field of Chinese medicines, relates to a kind of Chinese patent medicine for the treatment of hepatitis gravis.
Though background technology hepatitis gravis sickness rate is not high, only account for the 1%-3% of hepatitis, but because of China's hepatitis occurred frequently, much by the hepatitis gravis that hepatitis B causes, add the increase of medicamentous liver lesion, hepatitis gravis becomes the serious illness of infringement people ' s health, and is very harmful to people ' s health and social economy.
The state of an illness of hepatitis gravis is dangerous and complicated, complication is many, the treatment difficulty, the case fatality rate of big serial case generally all reaches 80%-90%, and primary disease is invaded person between twenty and fifty more, the stage that this age level is created the wealth for society just, no matter still all bearing the responsibility of supporting the old man, bringing up one's children socially in the family, it all is difficult to the appraisal saving its economic worth of being created of patient and social value more.
China's hepatitis is occurred frequently, and is much by the hepatitis gravis that hepatitis B causes, adds the increase of medicamentous liver lesion, and hepatitis gravis becomes the serious illness of infringement people ' s health.
At present, western modern medicine treatment hepatitis B uses that antiviral, antiinflammatory protect the liver, Comprehensive Treatments such as immunomodulating and fibrosis more, on the selection of medicine and curative effect, have many unfavorable aspect.
Summary of the invention the purpose of this invention is to provide the medicine of the treatment hepatitis gravis that therapeutic effect is good, toxic and side effects is little that a kind of pure Chinese medicine makes.
Medical material in the raw material of the present invention is formed and the weight portion proportioning is:
Mattress become 30-60 part, Radix Scutellariae 10-15 part, Rhizoma Coptidis 9-12 part, Radix Et Rhizoma Rhei 8-12 part,
Fructus Gardeniae 10-15 part, Semen Plantaginis 15-20 part, Poria 15-18 part, Rhizoma Atractylodis Macrocephalae 15-20 part,
Fructus Crataegi 15-20 part, Radix Salviae Miltiorrhizae 25-30 part, Radix Astragali 15-20 part, Radix Glycyrrhizae 3-5 part,
Rhizoma Osmundae 15-30 part and Herba Hedyotidis Diffusae 20-60 part.
Medical material in the raw material of the present invention is formed and preferred weight part proportioning is:
Mattress become 45 parts, 12 parts of Radix Scutellariaes, 10 parts of Rhizoma Coptidis, 10 parts of Radix Et Rhizoma Rhei,
12 parts of Fructus Gardeniaes, 17 parts of Semen Plantaginiss, 16 parts in Poria, 17 parts of the Rhizoma Atractylodis Macrocephalaes,
17 parts of Fructus Crataegis, 28 parts of Radix Salviae Miltiorrhizaes, 18 parts of the Radixs Astragali, 4 parts in Radix Glycyrrhizae,
40 parts of 26 parts of Rhizoma Osmundae and Herba Hedyotidis Diffusaes.
The method for making of medicine of the present invention and usage are: be decocted in water for oral dose, every day, potion divided secondary oral.
Chinese medicine is accumulating abundant clinical experience aspect the treatment viral hepatitis, and clinical research and experimentation have also confirmed the curative effect of Chinese medicine hepatitis B.Chinese medicine has multinomial effects such as antiinflammatory protects the liver, antiviral, anti-hepatic fibrosis, adjusting immunologic function; And Western medicine at anti-hepatitis virus, improve determined curative effect aspect the liver function.Thereby the therapy of combining Chinese and Western medicine hepatopathy has good prospect.
Prescription of the present invention adds flavor according to " Herba Artemisiae Scopariae Decoction " prescription in the Zhang Zhongjing treatise on Febrile Diseases and forms, and Herba Artemisiae Scopariae is a monarch drug in the side, and Herba Artemisiae Scopariae has choleretic effect, promotes biliary synthesizing, and alleviates hyperbilirubinemia, with the dampness removing jaundice eliminating.Radix Scutellariae is a ministerial drug, helps Herba Artemisiae Scopariae to strengthen function of gallbladder promoting heat clearing away effect.Assistant is with Rhizoma Coptidis, Fructus Gardeniae, Radix Et Rhizoma Rhei, and heat-clearing and toxic substances removing, dampness are assisted last two herbal medicines to strengthen thin the rushing down of liver and gall and had the right, damp and hot soothing the liver machine down, and then all diseases are from alleviating.Fructus Gardeniae can make serum bilirubin and serum paddy third, glutamic oxaloacetic transaminase, GOT obviously reduce, and pathological changes such as hepatic tissue focal necrosis, pericholangitis and lamellar necrosis are all had obvious protective effect.Radix Et Rhizoma Rhei heat clearing away, detoxifcation are captured, and it is foul stagnant to cleanse intestinal, suppresses the intestinal germ reproduction, reduce endotoxin and produce, and its purging FU-organs is let out turbid effect can remove hematocele and stagnant, reduces the absorption of ammonia.Semen Plantaginis, Poria, the Rhizoma Atractylodis Macrocephalae, Fructus Crataegi are messenger drug, and Semen Plantaginis eliminating dampness by diuresis diuresis is led damp and hot poison heresy and just divided by two.Poria, the Rhizoma Atractylodis Macrocephalae, Fructus Crataegi QI invigorating, spleen invigorating, stomach function regulating strengthen spleen transmitting and distributing the fluids function, and restriction bitter cold medicine impairing the spleen and stomach, Radix Glycyrrhizae profit and all medicines, modern pharmacological research shows that the Radix Astragali can promote hepatocyte to synthesize albumin, promote liver cell regeneration, reduce gamma globulin [3]Simultaneously, Radix Astragali energy human body immunity improving function strengthens cellular immunization [4]Radix Salviae Miltiorrhizae has protective effect and liver cell regeneration is had facilitation hepatic injury, and Radix Salviae Miltiorrhizae can make the fibroblast of In vitro culture that significant morphological change takes place, and suppresses the karyokinesis and the propagation of cell; Radix Salviae Miltiorrhizae can improve Liver Microcirculation, promote the recovery of sinus hepaticus blood flow, thereby Radix Salviae Miltiorrhizae has the effect of tangible anti-hepatic fibrosis.Rhizoma Osmundae, Herba Hedyotidis Diffusae are ministerial drug, and auxiliary monarch drug plays therapeutical effect, can play cell activity enhancing respectively, improve immunity, and the inductor internal interference is plain to be generated, and suppresses the effect of virus replication.
This shows that therapy of combining Chinese and Western medicine hepatitis gravis can effectively improve symptom, sign, the liver function of hepatitis patient, and its curative effect is better than simple western medicine therapy.
Chinese medicine of the present invention has significant curative effect to the course of disease short acute serious hepatitis and subacute severe hepatitis.
This medicine is made up of pure Chinese medicine, and therapeutic effect is good, toxic and side effects is little.
Chinese medicine of the present invention has better curative effect to hepatitis gravis.This Chinese medicine is treated 300 many cases patients through clinical experiment for many years and application, and effective percentage is more than 95%, and cure rate has good medical treatment effect and social benefit more than 90%.
Drug therapy hepatitis gravis of the present invention has obtained effect preferably, and laboratory report is as follows.
1. data and method
1.1 physical data
Select in January, 2003 to 2006 year December clinical definite acute, subacute severe hepatitis patient 50 examples.Be divided into treatment at random and organize 30 examples: wherein male 20 examples, women 10 examples, age 15-70 year, average 41.5 years old;
Matched group 20 examples: wherein male 12 examples, women 8 examples, age 13-66 year, average 38.7 years old.
Both have comparability by analysis.
1.2 Therapeutic Method
Two groups of patients all adopt the Western medicine colligation therapy, and western medical treatment comprises antiviral, protects the liver, regulates immunity, adjusts that aminoacid is unbalance, control is infected, replenishes albumen, control is hemorrhage, fall blood ammonia, keep water, electrolyte balance, replenishes enough heats.
The treatment group adds on this therapy basis uses Chinese medicine of the present invention.Gradation is oral, every day potion, 28 days courses of treatment.
1.3 observation index
Main patient's clinical symptoms, the sign of observing before and after the treatment changes and has that uncomplicated a situation arises, detects total bilirubin (TBIL) before and after the treatment, albumin (ALB), glutamate pyruvate transaminase (ALT), glutamic oxaloacetic transaminase, GOT (AST), thrombinogen mobility indexs such as (PTA) and changes.
1.4 curative effect determinate standard
Clinical cure: clinical symptoms and sign disappear, and it is normal that ALB and ALT recover;
Produce effects: cardinal symptom disappears or is clearly better, and ALB and ALT are normally basic or than being clearly better before the treatment, muscle power is clearly better;
Invalid: as not reach improvement standard or deterioration.
1.5 the statistical method data adopts x 2Check
2 results
2.1 two groups of patient's comprehensive therapeutic effects relatively saw Table 1 when finished the course of treatment.
Two groups of patient's comprehensive therapeutic effects relatively when table 1 finished the course of treatment
Group Example number (people) Cure Produce effects Invalid
The treatment group 30 7 18 5
Matched group 20 1 10 9
Compare P<0.01 with matched group
2.2 the variation of two groups of clinical leading indicators in patient treatment front and back relatively sees Table 2.
The variation of clinical leading indicator relatively before and after the table 2 liang group patient treatment
Annotate: *: compare P<0.05 △ behind the expression group internal therapy with before the treatment: compare P<0.05 after the treatment with before the treatment between the expression group
*: compare P<0.01 △ △ behind the expression group internal therapy with before the treatment: compare P<0.01 after the treatment with before the treatment between the expression group
Through the variation of clinical main biochemical indicator before and after two groups of patient treatments is compared, illustrate that treatment group curative effect obviously is better than matched group.
The specific embodiment
The following examples can make those skilled in the art more fully understand the present invention, but do not limit the present invention in any way.
Embodiment 1 increases based on bilirubin
Accurately take by weighing following raw material: mattress becomes 60g, Radix Scutellariae 10g, Rhizoma Coptidis 10g, Radix Et Rhizoma Rhei 12g, Fructus Gardeniae 12g, Semen Plantaginis 15g, Poria 15g, Rhizoma Atractylodis Macrocephalae 15g, Fructus Crataegi 15g, Radix Salviae Miltiorrhizae 25g, Radix Astragali 15g, Radix Glycyrrhizae 3g, Rhizoma Osmundae 15g, Herba Hedyotidis Diffusae 20g.Adopt conventional decocting method to decoct twice, make the about 300ml of decocting liquid.Every day, potion divided secondary oral, 28 days courses of treatment.Finish back check liver function bilirubin the course of treatment and recover normal, the transaminase descends, and clinical symptoms and sign disappear substantially, curative effect 92%.
Embodiment 2 based on the transaminase increase, abdominal distention
Accurately take by weighing following raw material: mattress becomes 45g, Radix Scutellariae 12g, Rhizoma Coptidis 9g, Radix Et Rhizoma Rhei 8g, Fructus Gardeniae 10g, Semen Plantaginis 20g, Poria 18g, Rhizoma Atractylodis Macrocephalae 17g, Fructus Crataegi 20g, Radix Salviae Miltiorrhizae 28g, Radix Astragali 18g, Radix Glycyrrhizae 4g, Rhizoma Osmundae 26g, Herba Hedyotidis Diffusae 60g.Adopt conventional decocting method to decoct twice, make the about 300ml of decocting liquid.
Every day, potion divided secondary oral, 28 days courses of treatment.Finish back check liver function bilirubin the course of treatment and obviously descend, the transaminase recovers normally, and clinical symptoms and sign disappear, curative effect 95%.
Embodiment 3 is reduced to the master with the thrombinogen mobility
Accurately take by weighing following raw material: mattress becomes 30g, Radix Scutellariae 15g, Rhizoma Coptidis 12g, Radix Et Rhizoma Rhei 10g, Fructus Gardeniae 15g, Semen Plantaginis 17g, Poria 16g, Rhizoma Atractylodis Macrocephalae 17g, Fructus Crataegi 17g, Radix Salviae Miltiorrhizae 30g, Radix Astragali 20g, Radix Glycyrrhizae 5g, Rhizoma Osmundae 30g, Herba Hedyotidis Diffusae 40g.Adopt conventional decocting method to decoct twice, make the about 300ml of decocting liquid.Every day, potion divided secondary oral, 28 days courses of treatment.Finish back check liver function bilirubin the course of treatment and obviously descend, the transaminase recovers normally, and the thrombinogen mobility is near normal, and clinical symptoms and sign disappear, curative effect 94%.

Claims (2)

1, a kind of medicine for the treatment of hepatitis gravis is characterized in that medical material composition and the weight portion proportioning in the raw material is:
Mattress become 30-60 part, Radix Scutellariae 10-15 part, Rhizoma Coptidis 9-12 part, Radix Et Rhizoma Rhei 8-12 part,
Fructus Gardeniae 10-15 part, Semen Plantaginis 15-20 part, Poria 15-18 part, Rhizoma Atractylodis Macrocephalae 15-20 part,
Fructus Crataegi 15-20 part, Radix Salviae Miltiorrhizae 25-30 part, Radix Astragali 15-20 part, Radix Glycyrrhizae 3-5 part,
Rhizoma Osmundae 15-30 part and Herba Hedyotidis Diffusae 20-60 part.
2,, it is characterized in that medical material composition and the weight portion proportioning in the raw material is according to the medicine of the described treatment hepatitis gravis of claim 1:
Mattress become 45 parts, 12 parts of Radix Scutellariaes, 10 parts of Rhizoma Coptidis, 10 parts of Radix Et Rhizoma Rhei,
12 parts of Fructus Gardeniaes, 17 parts of Semen Plantaginiss, 16 parts in Poria, 17 parts of the Rhizoma Atractylodis Macrocephalaes,
17 parts of Fructus Crataegis, 28 parts of Radix Salviae Miltiorrhizaes, 18 parts of the Radixs Astragali, 4 parts in Radix Glycyrrhizae,
40 parts of 26 parts of Rhizoma Osmundae and Herba Hedyotidis Diffusaes.
CN2009101172019A 2009-01-09 2009-01-09 Medicament for treating severe hepatitis Expired - Fee Related CN101461857B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2009101172019A CN101461857B (en) 2009-01-09 2009-01-09 Medicament for treating severe hepatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009101172019A CN101461857B (en) 2009-01-09 2009-01-09 Medicament for treating severe hepatitis

Publications (2)

Publication Number Publication Date
CN101461857A true CN101461857A (en) 2009-06-24
CN101461857B CN101461857B (en) 2011-02-16

Family

ID=40802792

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009101172019A Expired - Fee Related CN101461857B (en) 2009-01-09 2009-01-09 Medicament for treating severe hepatitis

Country Status (1)

Country Link
CN (1) CN101461857B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104161853A (en) * 2013-08-30 2014-11-26 郑州后羿制药有限公司 Traditional Chinese medicine composition for treating livestock and poultry hepatitis and preparation method thereof
CN104547635A (en) * 2014-12-27 2015-04-29 阚景平 Traditional Chinese medicine capsule for treating serious hepatitis and preparation method of traditional Chinese medicine capsule
CN110575521A (en) * 2019-05-20 2019-12-17 中国中医科学院广安门医院 Traditional Chinese medicine composition for treating chronic hepatitis B and hepatitis B-related compensatory cirrhosis and application

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104161853A (en) * 2013-08-30 2014-11-26 郑州后羿制药有限公司 Traditional Chinese medicine composition for treating livestock and poultry hepatitis and preparation method thereof
CN104547635A (en) * 2014-12-27 2015-04-29 阚景平 Traditional Chinese medicine capsule for treating serious hepatitis and preparation method of traditional Chinese medicine capsule
CN110575521A (en) * 2019-05-20 2019-12-17 中国中医科学院广安门医院 Traditional Chinese medicine composition for treating chronic hepatitis B and hepatitis B-related compensatory cirrhosis and application

Also Published As

Publication number Publication date
CN101461857B (en) 2011-02-16

Similar Documents

Publication Publication Date Title
CN101869665B (en) Chinese medicinal composition for treating necrospermia, asthenospermia oligospermia, or aspermatism
CN102284050B (en) Chinese medicine composition for treating infertility caused by cold uterus
CN101461857B (en) Medicament for treating severe hepatitis
CN103705687A (en) Traditional Chinese medicinal composition for preventing and treating early chronic renal failure and preparation method thereof
CN102698207A (en) Traditional Chinese medicine composition for treating hepatopathy and preparation method thereof
CN101940759B (en) Chinese medicinal composition for treating liver diseases and preparation method and application thereof
CN104225166A (en) Chinese medicine composition for treating amenorrhea and preparation method thereof
CN101428114B (en) Medicament for treating chronic hepatitis B, cirrhosis and liver ascites
CN102671102A (en) Chinese medicinal composition for treating chronic hepatitis
CN101897930A (en) Chinese medicinal herb for treating dysmenorrhoea disease
CN102671056B (en) Chinese medicinal composition for treating hepatitis and preparation method thereof
CN110101820B (en) A Chinese medicinal composition for treating obesity
CN103550470B (en) Healthy traditional Chinese medicine for children
CN103071079B (en) Traditional Chinese medicinal composition for treating prurigo nodularis
CN102935214B (en) Traditional Chinese medicinal composition for treating uremia
CN101703645B (en) Chinese medicinal composition for treating cervical vertebra hyperosteogeny
CN104840891A (en) Traditional Chinese medicine preparation used for treating alcoholic cardiomyopathy and preparation method thereof
CN104523965A (en) Nephritis treating traditional Chinese medicine composition
CN103495022A (en) Traditional Chinese medicine for adjuvant therapy of aids
CN103494939A (en) Traditional Chinese medicine for treating senile habitual constipation
CN103212033B (en) Drug composition for treating viral hepatitis
CN114209791B (en) Traditional Chinese medicine composition for treating autoimmune hepatitis by taking Yunnan rhizoma paridis as main raw material, and preparation method, preparation and application thereof
CN102772575A (en) Traditional Chinese medicine composition for treating chronic hepatitis B
CN108578560B (en) Traditional Chinese medicine composition for treating liver-kidney yin deficiency type autoimmune hepatitis and preparation method thereof
CN102335243B (en) Chinese medicinal composition for treating icteric hepatitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110216

Termination date: 20120109